A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• HER2-positive breast cancer is a significant clinical challenge.
• Current immunotherapies face limitations in targeting specificity and efficacy.

Purpose of the Study:

• To develop a nanobody-based immunotherapeutic strategy for HER2-positive breast cancer.
• To investigate the targeted delivery of anti-dinitrophenyl (anti-DNP) antibodies to HER2-expressing tumor cells.

Main Methods:

• Rational design of a nanobody activation immunotherapeutic.
• Selective redirection of anti-DNP antibodies to HER2-positive cancer cell surfaces.
• Evaluation of antibody-dependent cellular cytotoxicity (ADCC) for tumor cell destruction.

Main Results:

• The nanobody immunotherapeutic successfully redirected anti-DNP antibodies to HER2-positive breast cancer cells.
• Targeted cancer cell destruction was achieved through ADCC.
• Nanobodies demonstrated ease of expression, stability, and potential for humanization.

Conclusions:

• This nanobody activation immunotherapeutic offers a potent and selective strategy for targeting HER2-positive breast cancer.
• The adaptable nature of nanobodies suggests broad applicability for targeting various cell surface receptors in disease treatment.